S&P 500

5.321,41

0,25%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Aerpio Pharmaceuticals Inc (ARPO)
Aerpio Pharmaceuticals Inc (ARPO) Notícias

ARPO

Aerpio Pharmaceuticals (ARPO)

Aerpio Pharmaceuticals Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ARPO

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
21/06/2023	07:03	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
16/06/2023	16:14	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
28/04/2023	14:25	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
28/04/2023	13:47	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
28/04/2023	13:43	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
29/03/2023	17:19	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
29/03/2023	17:07	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
29/03/2023	07:02	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
28/03/2023	17:08	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
14/02/2023	08:02	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
09/11/2022	18:16	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
07/11/2022	08:05	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
04/11/2022	17:06	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
26/10/2022	17:50	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
11/10/2022	13:28	Edgar (US Regulatory)	Small Company Offering and Sale of Securities Without Registration (d)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
04/10/2022	17:02	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
26/09/2022	18:28	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
21/03/2022	07:08	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
07/09/2021	18:26	Edgar (US Regulatory)	Statement of Beneficial Ownership (sc 13d)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
31/08/2021	20:53	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
09/07/2021	08:31	TipRanks	Penny Stock Aerpio Pharmaceuticals’ Merger With Aadi Makes It A Buy, Says Analyst	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
21/06/2021	08:31	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (preliminary) (prem14a)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
17/09/2020	08:00	GlobeNewswire Inc.	Aravive Appoints Michael W. Rogers to Board of Directors	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
01/09/2020	17:30	PR Newswire (US)	Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-...	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
27/05/2020	17:30	PR Newswire (US)	Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation ...	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
12/05/2020	17:30	GlobeNewswire Inc.	Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (fo...	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
17/04/2020	17:46	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
12/03/2020	18:00	GlobeNewswire Inc.	Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
07/02/2020	20:20	Business Wire	Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Pr...	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc
08/01/2020	10:43	Business Wire	Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperem...	NASDAQ:ARPO	Aerpio Pharmaceuticals Inc